Research Article ISSN: 2349 – 7106

Asian Journal of Research in Chemistry and Pharmaceutical Sciences

Journal home page: www.ajrcps.com

BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF GEFITINIB IN TISSUE SAMPLES (BRAIN HOMOGENATE) BY USING RP-HPLC

Sagar Kishor Savale*[1]

[1*]Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.

ABSTRACT

The present study was aimed at developing a reversed phase high performance liquid chromatography (RP-HPLC) method for determination of Gefitinib (GFT) in Tissue Samples (Brain Homogenate) and hydrochlorothiazide was used as an internal standard. The separation was achieved by using C-18 column (Qualisil BDS C18, 250 mm x 4.6 mm I.D.) coupled with a guard column of silica, mobile phase was consisting of acetonitrile: water with 0.1% formic acid (50:50 v/v). The flow rate was 0.2 mL/min and the drug was detected using PDA detector at the wavelength of 254 nm. The experimental conditions, including the diluting solvent, mobile phase composition, column saturation and flow rate, were optimised to provide high-resolution and reproducible peaks. The developed method was validated in terms of linearity, recovery, precision, sensitivity (LOD and LOQ) and stability study (short and long-term stabilities, Freeze/thaw stability and post-preparative).

KEYWORDS

Isocratic, Gefitinib, RP-HPLC, Validation and Brain Homogenate samples.

Author for Correspondence:

Sagar Kishor Savale,
Department of Pharmaceutics,
R. C. Patel Institute of Pharmaceutical Education and Research,
Shirpur, Maharashtra, India.

Email: avengersagar16@gmail.com

INTRODUCTON

Gefitinib (N-(3-chlorofluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)-quinazolin-4- amine) is a type of drug called a tyrosine kinase inhibitor (TKI), also known as a cancer growth inhibitor. Molecular formula of GFT is $C_{22}H_{24}ClFN_4O_3$ and Molecular weight of Gefitinib (GFT) is 446.90 g/mol. GFTis highly lipophilic drug having a log P value is 3.2 respectively. Dissociation constant of GFT was 5.4-7.2. GFT is a white crystalline powder materials. GFT has maximum solubility in methanol and acetonitrile. Melting point of GFT was 194ºC

respectively. Reported λmax of GFT is 254 nm. This inhibits autophosphorylation of EGFR and blocks down stream signalling. There is no bio-analytical method for estimation of GFT in Tissue Samples (Brain Homogenate). Hence this study was aimed at developing a simple, rapid and sensitive method for estimation of analyte (GFT) in tissue samples (Brain Homogenate) by using RP-HPLC[1-3].

MATERIAL AND METHODS

Material

Gefitinib (GFT) supplied as a gift sample from Khandelwal Industries Pvt. Ltd (Mumbai, India). All solvents used were of HPLC grade. Formic acid, Methanol and acetonitrile were obtained from MERCK. Chem. Ltd (Mumbai, India).

Tissue samples (Brain Homogenate)

Brain Homogenate samples were obtained from Central Animal House Facility, R.C. Patel Institute of Pharmaceutical education and Research Shirpur. Registration number 651/PO/ReBi/S/02/CPCSEA. The rats were euthanasiazed by using CO_2 chamber (carcass disposal: Deep Burying under Soil). The rats were sacrificed and skull was cut open and the brain was carefully excised. Each brain tissue was quickly rinsed with normal saline solution. The brain tissue samples were homogenized with one volume of normal saline solution in a tissue homogenizer (Figure No.1). Brain homogenates were stored in a deep freezer at -70˚C until HPLC analysis.

Instrumentation

Analysis were carried out using an Agilent 1200 HPLC system (Agilent technologies, USA). The system was equipped with quaternary pump and photo diode-array detector (PDA). All data were acquired and processed using EZ chrome elite software version 3.3.2.

Chromatographic conditions

Chromatographic separation was performed by using C-18 column (Qualisil BDS C18, 250 mm x 4.6 mm I.D.) coupled with a guard column. Isocratic elution was performed with acetonitrile: water with 0.1% formic acid (50:50 v/v) at a flow rate of 0.2 mL/min. The mobile phase was selected to give proper resolution of peaks[4].

Plasma Samples processing and quality control (QC) samples

Certified reference standards of GFT was weighed accurately and transferred 100 mg of GFT as working standard into 100 mL of volumetric flask, add about 100 mL of methanol and sonicated (1000µg/mL solution). The working standard solutions was 100-400ng/mL solution[5].

Preparation of standard solutions of internal standard (IS)

Internal standard such as hydrochlorothiazide, add 100 mg of IS in 100ml of methanolic working solution (1000 µg/mL). The working standard solutions was 30 µg/mL solution

Preparation of Tissue samples (Brain Homogenate)

The whole procedure was carried out at room temperature. To 100µl of GFT standard solution 100 µl of blank brain homogenate sample, 100µl of IS hydrochlorothiazide (30µg/mL) were spiked and added extraction solvent 2mL of acetonitrile was added and vortexed mixture for 20 min. This sample was ultra centrifuged at 10,000 rpm for 10 min. The supernatant layer was collected and 20µl was analyzed by HPLC system[6-8].

Method development

Methods development was important to judge the quality, reliability and consistency of analytical results. It is the process for proving that analytical method is acceptable for use to measure the concentration of drugs[7].

Method validation

Validation of an analytical method is the process which is established by laboratory studies to evaluate the performance uniqueness of the procedure meet the requirements for its intended use. The validation process for analytical procedures begins with planned and systematic collection by the applicant of the validation data to support analytical procedures. The following are typical analytical performance characteristics which may be tested during methods validation: linearity, recovery, precision, sensitivity (LOD and LOQ) and stability study (short and long-term stabilities, Freeze/thaw stability and post-preparative). The linearity of a bioanalytical method is its ability to

elicit test results that are directly, or by a well-defined mathematical transformation, proportional to the concentration of analyte in sample within a given range (100-400ng/mL). Percent recovery of the proposed method was determined on the basis of standard addition method. The percent recovery as well as average percent recovery was calculated. Recovery should be assessed using minimum 9 determinations over minimum 3 concentrations level covering specified range. Recovery study was performed three different level 80%, 100% and 120%. The precision is the measure of either the degree of reproducibility or repeatability of analytical method. It provides an indication of random error. Intra-day precision was determined by analysing, the three different concentrations 200 ng/ml, 300 ng/ml and 400ng/ml for Brain Homogenate samples analysis, for three times in the same day and Inter-day variability was assessed using above mentioned three concentrations of Brain Homogenate samples were analysed by three different days, over a period of one week. Sensitivity refers to the smallest quantity that can be accurately measured. It also indicates the capacity of the method to measure small variations in concentration. Sensitivity of the proposed method were estimated in terms of Limit of Detection (LOD) and Limit of Quantitation (LOQ). For Brain Homogenate sample analysis 100-400 ng/mL. The linear regression equation of the calibration curve was used to determine the LOD and LOQ.The stability of GFTin brain homogenate samples was assessed under different storage conditions. Stability was expressed as the concentration ratio of analytes in sample under each storage condition against those in the freshly prepared sample. All stability assessments were assayed at three concentrations. Three samples were determined for short-term stability by putting them on the bench top at room temperature for 12 h and 24 h, respectively, prior to extraction. To evaluate freeze/thaw stability, three samples were subject to three freeze-thaw cycles with each cycle stepping from defrosting at room temperature to freezing at -20°C for 12 h. To determine the post-preparative stability, the extracted samples were stored in the sampler for 24 h. The long-term stability was performed by processing and analysing samples of brain homogenate kept at -20°C for 40 days[8-12].

RESULTS AND DISCUSSION

Method development

Mobile phase consisting of acetonitrile: water with 0.1% formic acid (50:50 v/v) was tried and drug was resolved properly. This method showed the best peak shape and ideal detection response. Furthermore, strong organic solvent in the reversed-phase chromatography can reduce static retention and shorten analysis time. Acetonitrile: water with 0.1% formic acid (50:50 v/v) mobile phase was optimized to give proper resolution of peaks (Figure No.2).

Method Validation

Linearity

For brain homogenate sample analysis linearity concentration in the range was 100-400 ng/mL. The correlation coefficients (R^2) of GFT in brain homogenate sample was found to be 0.9998.

Recovery, Precision and Sensitivity study

Recovery studies of brain homogenate samples for the proposed method were carried out, respective data is obtained and mentioned in (Table No.1) Recovery study was determined at three levels 80%, 100%, 120% at each level three determinations were performed. Intra-day and Inter-day precision of brain homogenate sample analysis was reported in (Table No.1). The % RSD for GFT was less than 2.0%. The results are showing that the proposed method was precise. Sensitivity of the proposed method were estimated in terms of Limit of Detection (LOD) and Limit of Quantitation (LOQ). The linear regression equation of the calibration curve was used to determine the LOD and LOQ. Limit of detection, limit of quantitation of brain homogenate sample analysis were reported in (Table No.1) respectively[13-14].

Stability study

The results demonstrated that GFT were stable in brain homogenate sample at room temperature for 12 h, in the sampling for 24 h and after three freeze-thaw cycles. All analytes were stable after stored at room temperature for 24 h. Even when stored in a

long-term freezer set at -20°C for 40 days, all analytes remained stable. Stability data for GFT shown in (Table No.2) and the results suggested that the tissue sample containing GFT can be stored under common laboratory conditions without any significant degradation of all analytes. Stability of GFT was investigated using different concentrations of QC brain homogenate samples. Excellent recoveries of GFT were observed at different storage conditions and no significant loss of GFT in either brain homogenate was observed.

Table No.1: Recovery, Precision and Sensitivity study

S.No	Recovery					
	Analysis	**Drug**	**Initial amount (ng/ml)**	**Added Amount (ng/ml)**	**% Recovery**	**% RSD (n = 3)**
1	Brain Homogenate	GFT	200	188	100.38	0.47
			200	200	99.49	0.28
			200	202	100.43	0.14
Precision						
	Analysis	**Drug**	**Con. (ng/ml)**	**Mean ± SD**	**% RSD (n = 3)**	**Mean ± SD**
2	Brain Homogenate	GFT	200	200.35 ± 0.47	0.16	200.15 ± 0.12
			300	300.29 ± 0.78	0.49	299.47 ± 0.30
			400	400.81 ± 0.66	0.21	399.11 ± 0.57
Sensitivity						
	Analysis		**Drug**	**LOD**		**LOQ**
3	Brain Homogenate		GFT	48.50 ± 0.24		179.15 ± 0.14

Table No.2: Stability study (Brain Homogenate Analysis)

S.No	Nominal (ng/ml)	3 freeze-thaw cycles	short-term room temperature		post-preparative stability (24 h)	long-term room temperature (40 d)
			(12 h)	(24 h)		
1	200	100.56 ± 1.61	99.18 ± 3.58	100.03 ± 5.89	104.13 ± 2.14	100.33 ± 6.73
2	300	100.11 ± 0.21	100.79 ± 1.38	100.41 ± 3.17	102.32 ± 0.55	105.86 ± 16.26
3	400	100.35 ± 1.43	99.62 ± 2.77	99.44 ± 6.98	100.74 ± 0.69	99.79 ± 8.38



Figure No.1: Brain Homogenate sample collection and analysis steps



Figure No.2: Typical chromatogram of GFTin Brain Homogenate Samples

CONCLUSION

In this study, we developed and validated a highly sensitive and specific RP-HPLC method for the quantitative analysis of GFT in brain homogenate samples. Validation of analytical method for estimation for GFT was determined by evaluating linearity, precision, recovery, sensitivity (LOD-LOQ) and stability (short and long-term stabilities, Freeze/thaw stability and post-preparative) in order to establish the suitability of analytical method. The method was validated in compliance with ICH guidelines is suitable for estimation of analytes with excellent recovery, precision, linearity and stability.

ACKNOWLEDGEMENT

I wish to acknowledge all those who are involved directly or indirectly for compilation of this article. It has been a great honour to work with such a professional.

CONFLICT OF INTEREST

We declare that we have no conflict of interest.

BIBILIOGRAPHY

1. Savale S. Simultaneous Determination of Curcumin and Gefitinib in Pure Form by Using UV Spectrophotometric Method, *Hygeia: journal for drugs and medicines,* 9(1), 2017, 1-8.
2. Savale S K. UV Spectrophotometric Method Development and Validation for Quantitative Estimation of Halcinonide, *Asian Journal of Biomaterial Research,* 3(3), 2017, 22-25.
3. Savale S K. UV Spectrophotometric Method Development and Validation for Quantitative Estimation of Curcumin, *Asian Journal of Biomaterial Research,* 3(4), 2017, 14-18.
4. Savale S K. UV Spectrophotometric Method Development and Validation for Quantitative Estimation of Paracetamol, *Asian Journal of Biomaterial Research,* 3(4), 2017, 33-37.
5. Savale S K. UV Spectrophotometric Method Development and Validation for Quantitative Estimation of Azelastine HCl, *Asian Journal of Biomaterial Research,* 3(5), 2017, 1-5.
6. Savale S K. Development and Validation of RP-HPLC Method for Estimation of Vildagliptin, *Asian Journal of Biomaterial Research,* 3(5), 2017, 6-11.
7. Sultana R, Bachar S C, Rahman F. Development and validation of stability indicating assay method of Vildagliptin in bulk and tablet dosage form by RP-HPLC, *International journal of pharmacy and life sciences,* 4(4), 2013, 2530-2534.
8. Singh N, Ahmad A. Spectrophotometric and spectroscopic studies of charge transfer complex of 1-Naphthylamine as an electron

donor with picric acid as an electron acceptor in different polar solvents, *Journal of Molecular Structure,* 977(1-3), 2010, 197-202.

9. Kucera R, Sochor J, Klimes J, Dohnal J. Use of the zirconia-based stationary phase for separation of ibuprofen and its impurities, *Journal of Pharmaceutical and Biomedical Analysis,* 38(4), 2005, 609-618.
10. Asmus P A. Determination of 2-(4-isobutylphenyl) propionic acid in bulk drug and compressed tablets by reversed-phase high-performance liquid chromatography, *Journal of Chromatography-A,* 331(1), 1985, 169-176.
11. Gnana Raja M, Geetha G, Sangaranarayanan A. Simultaneous, Stability Indicating Method Development and Validation for Related Compounds of Ibuprofen and Paracetamol Tablets by RP-HPLC Method, *Journal of Chromatography Separation Techniques,* 3(8), 2012, 1-5.
12. Quaglia M G, Donati E, Fanali S, Catarcini P. Ibuprofen quality control by electro chromatography, *Farmaco,* 58(9), 2003, 699-705.
13. Huidobro A, Ruperez F, Barbas C. Tandem column for the simultaneous determination of arginine, ibuprofen and related impurities by liquid chromatography, *Journal of chromatography-A,* 1119(1-2), 2006, 238-245.
14. Stubberud K, Callmer K, Westerlund D. Partial filling-micellar electrokinetic chromatography optimization studies of ibuprofen, codeine and degradation products, and coupling to mass spectrometry, *Part II, Electrophoresis,* 24(6), 2003, 1008-1015.

Please cite this article in press as: Sagar Kishor Savale. Bioanalytical method development and validation for estimation of gefitinib in tissue samples (brain homogenate) by using Rp-Hplc, *Asian Journal of Research in Chemistry and Pharmaceutical Sciences,* 5(2), 2017, 76-82.